Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11528MR)

This product GTTS-WQ11528MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11528MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14134MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ6463MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ10858MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ1205MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ14445MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ13984MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ2159MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ2635MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 592
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW